Substantial progress in the treatment of atherosclerotic complications – in particular in secondary prevention – has led to a significant reduction of recurrent cardiovascular events. This has been through the use of pharmacological strategies including lipid-lowering drugs such as statins, beta-blockers, angiotensin-converting ensyme inhibitors and angiotensin receptor blockers, along with the introduction of early percutaneous coronary intervention in acute coronary syndrome with consecutive application of dual antiplatelet therapy.
Atherosclerosis
Atherosclerosis
Article
Drug-coated Balloons short
Article
Statins and Insulin Resistance
Read time: 1h 1m 1s
About
Media
Watch time: 4m 53s
Watch time: 4m 57s
Watch time: 8m 2s
Watch time: 3m 25s
Watch time: 4m 43s
Watch time: 4m 14s
Watch time: 7m 48s
Watch time: 7m 44s
Watch time: 10m 34s
Watch time: 9m 40s
Articles
The Million Hearts Initiative - Targeting Key Drivers of Cardiovascular Mortality from a Medical Specialty Society Perspective
Citation:
US Cardiology 2012;9(1):66-70
- Views:
385
- Downloads:
0
Support for Combined Administration of Antihypertensive and Lipid-lowering Agents to Reduce Cardiovascular Events—The Emergence of the Multipill
Citation:
US Cardiology 2006;3(2):20–1
- Views:
83
- Downloads:
0
Interventional Cardiology for Coronary Artery Disease
Citation:
European Cardiovascular Disease 2006;2(1):70–2
- Views:
194
- Downloads:
0
A Review of Angiotensin Receptor Blocker-based Therapies at all Levels of Cardiovascular Risk
Citation:
European Cardiology 2011;7(4):254–6
- Views:
534
- Downloads:
0